Core Laboratories Company Insiders
CLB Stock | USD 16.97 0.21 1.22% |
About 56% of Core Laboratories' corporate insiders are selling. The analysis of insiders' sentiment of trading Core Laboratories NV stock suggests that many insiders are alarmed at this time. Core Laboratories employs about 3.6 K people. The company is managed by 36 executives with a total tenure of roughly 190 years, averaging almost 5.0 years of service per executive, having 100.0 employees per reported executive.
Lawrence Bruno Chairman Chairman of the Supervisory Board, President, Chief Executive Officer, Chief Operating Officer |
David Demshur Chairman Independent Chairman of the Board of Supervisory Directors and Chief Executive Officer |
Core Laboratories' Insider Buying Vs Selling
44
Selling | Buying |
Latest Trades
2020-05-07 | Jan Willem Sodderland | Acquired 600 @ 17.07 | View | ||
2020-02-03 | Lawrence Bruno | Acquired 3000 @ 34.86 | View | ||
2020-01-02 | Mark F. Elvig | Disposed 600 @ 37.93 | View | ||
2019-08-13 | Gregory Barry Barnett | Acquired 1000 @ 40 | View | ||
2019-03-11 | Kevin Daniels | Disposed 428 @ 66.25 | View | ||
2018-10-29 | Jan Willem Sodderland | Acquired 200 @ 85.76 | View | ||
2018-08-14 | Kevin Daniels | Disposed 73 @ 112.63 | View | ||
2017-02-01 | Michael Straughen | Acquired 106 @ 118.65 | View | ||
2017-01-30 | Martha Z Carnes | Acquired 200 @ 115.2 | View | ||
2016-02-02 | Jan Willem Sodderland | Acquired 300 @ 93.9 | View | ||
2015-05-12 | Michael C Kearney | Disposed 1000 @ 128.52 | View | ||
2014-11-17 | Mark F Elvig | Disposed 1000 @ 138.03 | View | ||
2014-07-28 | Richard L Bergmark | Acquired 7000 @ 147.31 | View | ||
2014-03-07 | Michael Kearney | Disposed 2000 @ 193 | View | ||
2014-02-14 | Mark Elvig | Disposed 1500 @ 186.64 | View | ||
2013-10-21 | Monty L Davis | Disposed 5704 @ 197.33 | View | ||
2013-08-07 | Richard Bergmark | Disposed 20000 @ 149.58 | View | ||
2013-07-25 | Monty L Davis | Disposed 5948 @ 149.12 | View |
Monitoring Core Laboratories' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Core |
Core Laboratories' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Core Laboratories' future performance. Based on our forecasts, it is anticipated that Core will maintain a workforce of about 3900 employees by May 2024.Core Laboratories' latest congressional trading
Congressional trading in companies like Core Laboratories, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Core Laboratories by those in governmental positions are based on the same information available to the general public.
2018-12-10 | Representative Thomas J. Rooney | Disposed $15K to $50K | Verify | ||
2018-04-24 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
2018-04-24 | Senator Shelley M Capito | Acquired Under $15K | Verify |
Core Laboratories Management Team Effectiveness
The company has Return on Asset of 0.0605 % which means that on every $100 spent on assets, it made $0.0605 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1768 %, implying that it generated $0.1768 on every 100 dollars invested. Core Laboratories' management efficiency ratios could be used to measure how well Core Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.15. The current year's Return On Capital Employed is expected to grow to 0.21. At present, Core Laboratories' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 26 M, whereas Total Assets are forecasted to decline to about 550.2 M.As of April 23, 2024, Common Stock Shares Outstanding is expected to decline to about 40.8 M. In addition to that, Net Income Applicable To Common Shares is expected to decline to about 21.3 M
Core Laboratories Workforce Comparison
Core Laboratories NV is number one stock in number of employees category among related companies. The total workforce of Energy industry is currently estimated at about 16,775. Core Laboratories totals roughly 3,600 in number of employees claiming about 21% of equities under Energy industry.
Core Laboratories Profit Margins
The company has Net Profit Margin of 0.07 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.13 %, which entails that for every 100 dollars of revenue, it generated $0.13 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.2 | 0.1845 |
|
| |||||
Operating Profit Margin | 0.14 | 0.1055 |
|
|
Core Laboratories Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Core Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on Core Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Core Laboratories insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2023-06-01 | 1.5714 | 11 | 7 | 65,005 | 35,434 |
2022-12-01 | 0.4286 | 6 | 14 | 133,922 | 205,018 |
2022-06-01 | 0.6 | 6 | 10 | 27,675 | 33,386 |
2022-03-01 | 1.75 | 7 | 4 | 215,566 | 334.00 |
2021-12-01 | 0.5 | 8 | 16 | 79,962 | 111,193 |
2021-09-01 | 1.8 | 9 | 5 | 31,546 | 302.00 |
2021-06-01 | 0.8571 | 12 | 14 | 112,884 | 111,265 |
2021-03-01 | 2.0 | 6 | 3 | 156,152 | 175.00 |
2020-12-01 | 0.4545 | 5 | 11 | 21,622 | 30,301 |
2020-09-01 | 0.5 | 1 | 2 | 105.00 | 152.00 |
2020-06-01 | 0.9048 | 19 | 21 | 114,026 | 31,400 |
2020-03-01 | 2.25 | 9 | 4 | 288,626 | 774.00 |
2019-12-01 | 0.4167 | 5 | 12 | 66,440 | 102,746 |
2019-09-01 | 1.5 | 3 | 2 | 3,105 | 146.00 |
2019-06-01 | 0.7692 | 20 | 26 | 27,440 | 14,293 |
2019-03-01 | 1.1429 | 8 | 7 | 128,538 | 908.00 |
2018-12-01 | 0.5833 | 7 | 12 | 63,135 | 84,730 |
2018-09-01 | 0.4545 | 5 | 11 | 655.00 | 944.00 |
2018-06-01 | 0.7778 | 14 | 18 | 16,269 | 16,155 |
2018-03-01 | 1.5 | 12 | 8 | 100,592 | 8,279 |
2017-12-01 | 0.6364 | 7 | 11 | 85,705 | 116,538 |
2017-09-01 | 0.5 | 1 | 2 | 125.00 | 160.00 |
2017-06-01 | 4.0 | 8 | 2 | 9,146 | 71.00 |
2017-03-01 | 1.0833 | 13 | 12 | 79,994 | 5,103 |
2016-12-01 | 0.5 | 6 | 12 | 38,423 | 53,104 |
2016-09-01 | 0.6667 | 2 | 3 | 1,460 | 160.00 |
2016-06-01 | 2.6667 | 8 | 3 | 9,398 | 71.00 |
2016-03-01 | 0.9286 | 13 | 14 | 108,443 | 8,377 |
2015-12-01 | 0.5 | 6 | 12 | 55,935 | 74,910 |
2015-09-01 | 1.0 | 2 | 2 | 425.00 | 160.00 |
2015-06-01 | 1.6 | 8 | 5 | 9,916 | 2,656 |
2015-03-01 | 1.25 | 10 | 8 | 87,569 | 5,760 |
2014-12-01 | 0.4 | 6 | 15 | 61,104 | 108,886 |
2014-06-01 | 1.1 | 11 | 10 | 8,336 | 4,842 |
2014-03-01 | 1.2222 | 11 | 9 | 45,155 | 8,681 |
2013-12-01 | 0.3846 | 5 | 13 | 65,207 | 97,235 |
2013-06-01 | 1.2222 | 11 | 9 | 10,116 | 7,050 |
2013-03-01 | 0.8333 | 10 | 12 | 63,670 | 17,919 |
2012-12-01 | 0.55 | 11 | 20 | 67,731 | 90,174 |
2012-09-01 | 0.625 | 5 | 8 | 9,265 | 9,275 |
2012-06-01 | 1.0714 | 15 | 14 | 16,124 | 19,031 |
2012-03-01 | 0.8333 | 10 | 12 | 66,018 | 42,349 |
2011-12-01 | 1.0 | 2 | 2 | 409.00 | 506.00 |
2011-09-01 | 0.0625 | 1 | 16 | 9.00 | 271,598 |
2011-06-01 | 1.3571 | 19 | 14 | 82,900 | 33,354 |
2011-03-01 | 0.4444 | 4 | 9 | 5,000 | 16,381 |
2010-12-01 | 0.5 | 1 | 2 | 400.00 | 506.00 |
2010-09-01 | 0.1765 | 6 | 34 | 24,000 | 483,626 |
2010-06-01 | 1.2 | 18 | 15 | 39,240 | 8,332 |
2010-03-01 | 0.2857 | 4 | 14 | 2,500 | 191,229 |
2009-12-01 | 0.125 | 3 | 24 | 600.00 | 214,113 |
2009-09-01 | 1.0 | 12 | 12 | 18,942 | 14,093 |
2009-06-01 | 0.7 | 7 | 10 | 6,400 | 4,049 |
2009-03-01 | 1.4444 | 13 | 9 | 5,967 | 3,470 |
2008-12-01 | 0.5 | 1 | 2 | 200.00 | 253.00 |
2008-09-01 | 0.3333 | 6 | 18 | 4,452 | 34,220 |
2008-06-01 | 0.6667 | 4 | 6 | 4,600 | 3,363 |
2008-03-01 | 0.0338 | 9 | 266 | 137,400 | 325,183 |
2007-09-01 | 0.0286 | 6 | 210 | 12,000 | 165,605 |
2007-06-01 | 0.1667 | 9 | 54 | 8,000 | 16,993 |
2007-03-01 | 0.0879 | 32 | 364 | 1,321,392 | 2,106,651 |
2006-09-01 | 5.0 | 5 | 1 | 10,000 | 2,000 |
2006-06-01 | 0.5714 | 4 | 7 | 21,000 | 10,984 |
2005-06-01 | 1.0 | 4 | 4 | 76,199 | 76,199 |
2002-06-01 | 1.0 | 2 | 2 | 37,712 | 38,487 |
Core Laboratories Notable Stakeholders
A Core Laboratories stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Core Laboratories often face trade-offs trying to please all of them. Core Laboratories' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Core Laboratories' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Lawrence Bruno | Chairman of the Supervisory Board, President, Chief Executive Officer, Chief Operating Officer | Profile | |
David Demshur | Independent Chairman of the Board of Supervisory Directors and Chief Executive Officer | Profile | |
Tahera Khan | Vice President Human Resources | Profile | |
Gwendolyn Schreffler | Senior Vice President, Corporate Development and Investor Relations | Profile | |
Michael Flecker | Vice President Production Enhancement | Profile | |
Christopher Hill | Chief Financial Officer, Senior Vice President | Profile | |
Alastair Crombie | Vice President Reservoir Description | Profile | |
Mark Elvig | Senior Vice President, Secretary, and General Counsel | Profile | |
David Hume | Vice President Reservoir Description | Profile | |
Kevin Daniels | Vice President, Chief Accounting Officer | Profile | |
James Gresham | Senior Vice President Business Development | Profile | |
Peter Boks | Vice President Reservoir Description | Profile | |
Jeffrey West | Vice President Production Enhancement | Profile | |
Dumas | Vice President Business Development | Profile | |
Monty Davis | COO and Sr. VP | Profile | |
Charles Dunlap | Independent Member of the Board of Supervisory Directors | Profile | |
Richard Bergmark | CFO, Executive VP and Supervisory Director | Profile | |
Michael Kearney | Independent Supervisory Director | Profile | |
Margaret Kempen | Independent Member of the Board of Supervisory Directors | Profile | |
Lucia Geuns | Independent Member of the Board of Supervisory Directors | Profile | |
Jan Sodderland | Independent Member of the Board of Supervisory Directors | Profile | |
Sow Teo | Treasurer VP | Profile | |
Chris Hill | Chief Accounting Officer and VP | Profile | |
Monique Eeuwijk | Non-Executive Independent Member of the Supervisory Board | Profile | |
D Ogren | Member of the Supervisory Board | Profile | |
Harvey Klingensmith | Non-Executive Independent Member of the Supervisory Board | Profile | |
Michael Straughen | Non-Executive Independent Member of the Supervisory Board | Profile | |
John Ogren | Member of the Supervisory Board | Profile | |
Gwendolyn MBA | Senior Relations | Profile | |
J Dumas | Vice President Business Development | Profile | |
Martha Carnes | Presiding Non-Executive Lead Independent Member of the Supervisory Board | Profile | |
Jacobus Schouten | Managing Director | Profile | |
Kwaku Temeng | Non-Executive Independent Member of the Supervisory Board | Profile | |
Gregory Barnett | Non-Executive Independent Member of the Supervisory Board | Profile | |
Mark Tattoli | Senior Vice President General Counsel, Secretary | Profile | |
Gwendolyn Gresham | Senior Vice President Corporate Development and Investor Relations | Profile |
About Core Laboratories Management Performance
The success or failure of an entity such as Core Laboratories often depends on how effective the management is. Core Laboratories management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Core management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Core management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.08 | 0.15 | |
Return On Capital Employed | 0.11 | 0.21 | |
Return On Assets | 0.06 | 0.10 | |
Return On Equity | 0.16 | 0.32 |
The data published in Core Laboratories' official financial statements usually reflect Core Laboratories' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Core Laboratories. For example, before you start analyzing numbers published by Core accountants, it's critical to develop an understanding of what Core Laboratories' liquidity, profitability, and earnings quality are in the context of the Energy Equipment & Services space in which it operates.
Please note, the presentation of Core Laboratories' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Core Laboratories' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Core Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Core Laboratories NV. Please utilize our Beneish M Score to check the likelihood of Core Laboratories' management manipulating its earnings.
Core Laboratories Workforce Analysis
Traditionally, organizations such as Core Laboratories use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Core Laboratories within its industry.Core Laboratories Manpower Efficiency
Return on Core Laboratories Manpower
Revenue Per Employee | 141.6K | |
Revenue Per Executive | 14.2M | |
Net Income Per Employee | 10.2K | |
Net Income Per Executive | 1M | |
Working Capital Per Employee | 30.2K | |
Working Capital Per Executive | 3M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Core Stock analysis
When running Core Laboratories' price analysis, check to measure Core Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Core Laboratories is operating at the current time. Most of Core Laboratories' value examination focuses on studying past and present price action to predict the probability of Core Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Core Laboratories' price. Additionally, you may evaluate how the addition of Core Laboratories to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities |
Is Core Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.72) | Dividend Share 0.04 | Earnings Share 0.51 | Revenue Per Share 10.92 | Quarterly Revenue Growth 0.005 |
The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.